中国经济网北京2月12日讯 索宝蛋白(603231.SH)今日收报18.70元，跌幅5.22%。目前该股股价处于 破发状态。 2023年12月15日，索宝蛋白在上交所主板上市，发行股份数量为4,786.48万股，无老股转让，全部 为公开发行新股，发行价格为21.29元/股，保荐机构（主承销商）为东吴证券股份有限公司，保荐代表 人为庞家兴、祁俊伟；联席主承销商为南京证券股份有限公司。 索宝蛋白首次公开发行募集资金总额101,904.16万元，募集资金净额97,945.57万元。索宝蛋白最终 募集资金净额比原计划多42,487.31万元。索宝蛋白2023年12月8日发布的首次公开发行股票并在主板上 市招股说明书显示，公司拟募集资金55,458.26万元，用于3万吨大豆组织拉丝蛋白生产线建设项目、 5000吨大豆颗粒蛋白生产线建设项目、75T中温中压高效煤粉锅炉项目、补充流动资金。 索宝蛋白公开发行新股的发行费用合计3,958.59万元（不含税），其中承销及保荐费用2,735.85万 元。 (责任编辑：何潇) ...

索宝蛋白首次公开发行募集资金总额101,904.16万元，募集资金净额97,945.57万元。索宝蛋白最终募集 资金净额比原计划多42,487.31万元。索宝蛋白2023年12月8日发布的首次公开发行股票并在主板上市招 股说明书显示，公司拟募集资金55,458.26万元，用于3万吨大豆组织拉丝蛋白生产线建设项目、5000吨 大豆颗粒蛋白生产线建设项目、75T中温中压高效煤粉锅炉项目、补充流动资金。 索宝蛋白公开发行新股的发行费用合计3,958.59万元(不含税)，其中承销及保荐费用2,735.85万元。 2023年12月15日，索宝蛋白在上交所主板上市，发行股份数量为4,786.48万股，无老股转让，全部为公 开发行新股，发行价格为21.29元/股，保荐机构(主承销商)为东吴证券股份有限公司，保荐代表人为庞 家兴、祁俊伟；联席主承销商为南京证券（601990）股份有限公司。 中国经济网北京2月3日讯索宝蛋白（603231）(603231.SH)今日收报19.17元，跌幅1.03%，总市值36.70 亿元。目前该股股价处于破发状态。 ...

Core Viewpoint - The company is expected to achieve significant growth in net profit for 2025, with projections indicating a year-on-year increase of 46.89% to 57.62% for net profit attributable to shareholders, and 56.03% to 66.07% for net profit after deducting non-recurring gains and losses [1] Group 1: Financial Performance - For 2025, the company forecasts a net profit attributable to shareholders of 1.78 to 1.91 billion yuan, and a net profit after deducting non-recurring gains and losses of 1.71 to 1.82 billion yuan [1] - In Q4 2025, the company anticipates a net profit of 0.31 to 0.44 billion yuan, representing a year-on-year growth of 6.1% to 50.2% [1] - The projected revenue for 2025 to 2027 is 17.04 billion yuan, 18.63 billion yuan, and 22.66 billion yuan, with year-on-year growth rates of 9.53%, 9.36%, and 21.63% respectively [2] Group 2: Operational Strategy - The company focuses on high-end manufacturing, energy optimization, and lean management to achieve significant cost reductions and efficiency improvements [1] - The management team actively monitors raw material market trends to capitalize on procurement opportunities, effectively lowering the cost of non-GMO soybean procurement [1] - New high-margin production capacities are expected to come online by the end of 2026, contributing to revenue growth and improving product structure [1] Group 3: Future Projections - The company expects to launch a 30,000-ton soybean textured protein project and a high-end soybean protein production line by December 2026 and June 2027, respectively [1] - The new products, including textured protein and high-end soybean protein, are anticipated to have high profit margins, which will support revenue growth as production capacity is released [1] - The projected net profit for 2025 to 2027 is 1.85 billion yuan, 2.00 billion yuan, and 2.82 billion yuan, with respective year-on-year growth rates of 52.54%, 7.99%, and 41.34% [2]

Group 1 - Shanghai Bunge plans to reduce its stake in Suobao Protein by up to 5,743,615 shares, representing no more than 3% of the total share capital [1] - The reduction will occur through a combination of centralized bidding and block trading, with a maximum of 1,914,500 shares (1% of total share capital) through centralized bidding and 3,829,115 shares (2% of total share capital) through block trading [1] - As of the announcement date, Shanghai Bunge holds 7,179,715 shares, accounting for 3.75% of the total share capital, all of which were acquired before the company's IPO [1] Group 2 - Suobao Protein was listed on the Shanghai Stock Exchange on December 15, 2023, with an issuance of 47,864,800 shares at a price of 21.29 yuan per share, raising a total of 1,019.04 million yuan [2] - The net proceeds from the offering amounted to 979.46 million yuan, exceeding the original plan by 424.87 million yuan [2] - The funds raised will be allocated to the construction of a 30,000-ton soybean textured protein production line, a 5,000-ton soybean granular protein production line, a 75T medium-temperature and medium-pressure efficient coal powder boiler project, and to supplement working capital [2]